Stock listing

BMV:RYTM Rhythm Pharmaceuticals, Inc. Acciones

Mexican listing (BMV) of Rhythm Pharmaceuticals, Inc. · home listing NASDAQ:RYTM

Follow Rhythm Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:RYTM

$86.17 USD -1.80 (-2.0%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:RYTM

Since Jul 6, 2026 -22.8% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$85.91 – $88.62 USDOct 16, 2026
Volume
364,054 sharesOct 16, 2026
Market value
$5.93B USDAt the close on Oct 16, 2026 · price × 68.85M shares outstanding
Rhythm Pharmaceuticals, Inc. logo
Ticker
BMV:RYTM
Asset type
Stock
Exchange
BMV
Currency
MXN

What changed lately

Calls

Replays

  • Rhythm Pharmaceuticals (NASDAQ:RYTM) Q2 2026 Earnings Call

    Tue, Aug 04, 2026 · 8:00 AM ET

    Watch Transcript

  • Rhythm Pharmaceuticals (NASDAQ:RYTM) Q1 2026 Earnings Call

    Tue, May 05, 2026 · 8:00 AM ET

    Watch Transcript

  • Rhythm Pharmaceuticals (NASDAQ:RYTM) Q4 2025 Earnings Call

    Thu, Feb 26, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

Oct 13, 2026

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

Sep 22, 2026

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

Sep 10, 2026

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

Aug 24, 2026

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

Aug 17, 2026

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

Aug 11, 2026

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Aug 4, 2026

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

Aug 4, 2026

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Jul 21, 2026

Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

Jul 8, 2026

All Rhythm Pharmaceuticals, Inc. news

Decks

Rhythm Pharmaceuticals, Inc. on 6ix

News releases
37 in the last 12 months · 220 in all · newest Oct 13, 2026 · oldest 2019
Calls
21 calls with a replay · 21 with a transcript · latest Aug 4, 2026
Decks
57 decks · latest September 2026

Where Rhythm Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RYTM · Home listingNASDAQUnited StatesUSD
LS Exchange:A2H5A0LS ExchangeGermanyEUR
Lang & Schwarz:A2H5A0Lang & SchwarzGermanyEUR
gettex:1RVgettexGermanyEUR
Tradegate:1RVTradegateGermanyEUR
BMV:RYTM · This pageBMVMexicoMXN
BOATS:RYTMBOATSUnited StatesUSD
Frankfurt:1RVFrankfurtGermanyEUR
BIVA:RYTMBIVAMexicoMXN
Dusseldorf:1RVDusseldorfGermanyEUR
Munich:1RVMunichGermanyEUR
Stuttgart:1RVStuttgartGermanyEUR
Xetra:1RVXetraGermanyEUR

Log in to ask 6ix AI your own questions about Rhythm Pharmaceuticals, Inc.